The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Relmada Therapeutics Inc shares valued at $86,060 were purchased by Kelly Paul Edward on May 16 ’25. At $0.43 per share, Kelly Paul Edward acquired 200,000 shares. The insider’s holdings grew to 412,295 shares worth approximately $0.29 million following the completion of this transaction.
Also, Shenouda Maged purchased 90,000 shares, netting a total of over 43,686 in proceeds. Following the buying of shares at $0.49 each, the insider now holds 228,335 shares.
Before that, Shenouda Maged had added 60,000 shares to its account. In a trade valued at $31,422, the Chief Financial Officer bought Relmada Therapeutics Inc shares for $0.52 each. Upon closing the transaction, the insider’s holdings increased to 60,000 shares, worth approximately $0.2 million.
As published in a research note from Mizuho on December 05, 2024, Relmada Therapeutics Inc [RLMD] has been rated down from an Outperform to a Neutral and the price target has been revised to $1 from $23. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid September. As of June 05, 2024, Goldman has decreased its “Neutral” rating to a “Sell” for RLMD. Earlier on October 14, 2022, Truist downgraded its rating. Their new recommendation was “a Hold” for RLMD stock which previously was a “a Buy”.
Analyzing RLMD Stock Performance
On last trading session,, Relmada Therapeutics Inc [NASDAQ: RLMD] plunged -7.87% to $0.71. The stock’s lowest price that day was $0.69, but it reached a high of $0.7869 in the same session. During the last five days, there has been a drop of approximately -13.88%. Over the course of the year, Relmada Therapeutics Inc shares have jumped approximately 35.81%.
Support And Resistance Levels for Relmada Therapeutics Inc (RLMD)
RSI (Relative Strength Index) is 56.65 on the 14-day chart, showing neutral technical sentiment.
Is Relmada Therapeutics Inc subject to short interest?
Stocks of Relmada Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.91 million shares to 1.13 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 2.03 million shares. A decline of -80.53% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.11 of the overall float, the days-to-cover ratio (short ratio) decline to 1.11.
Which companies own the most shares of Relmada Therapeutics Inc (RLMD)?
In terms of Relmada Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 809.09% from the previous closing price of $0.77. Analysts anticipate Relmada Therapeutics Inc stock to reach 8 by 2025, with the lowest price target being 2. In spite of this, 1 analysts ranked Relmada Therapeutics Inc stock as Sell at the end of 2025.
